Mitigate the risk of Hop Latent Viroid

As part of our continuous effort to support the spread of best practices in the industry, we’d like to take this opportunity to share the steps Segra and many of our clients are taking to mitigate the risk of Hop Latent Viroid (HLVd).
‍
Dr. John Brunstein, our Chief Scientific Officer, and our Tissue Culture team have assembled a document outlining best practices for detecting, managing, and mitigating HLVd. As a Ph.D. virologist, Dr. Brunstein speaks with a high level of qualification on this specific subject.
‍
We hope you find this information valuable. Our team is ready to answer your questions and provide support. Please reach out if you need help.